{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:05:25Z","timestamp":1788192325384,"version":"build-2803163510"},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ZX1312A"],"award-info":[{"award-number":["01ZX1312A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.jid.2020.06.019","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T17:53:52Z","timestamp":1599674032000},"page":"316-324.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance"],"prefix":"10.1016","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5042-3632","authenticated-orcid":false,"given":"John W.","family":"Frew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-4169","authenticated-orcid":false,"given":"Angelo V.","family":"Marzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7689-4130","authenticated-orcid":false,"given":"Kerstin","family":"Wolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4888-8630","authenticated-orcid":false,"given":"Olivier","family":"Join-Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1171-4917","authenticated-orcid":false,"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4256-478X","authenticated-orcid":false,"given":"Michelle A.","family":"Lowes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6079-4517","authenticated-orcid":false,"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2020.06.019_bib1","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","article-title":"North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management","volume":"81","author":"Alikhan","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMc1811317","article-title":"Inhibition of the interleukin-36 pathways for the treatment of generalized pustular psoriasis","volume":"380","author":"Bachelez","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2020.06.019_bib3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/08820139.2016.1230867","article-title":"Interferon-gamma (IFN-\u03b3) is elevated in wound exudate from hidradenitis suppurativa","volume":"46","author":"Banerjee","year":"2017","journal-title":"Immunol Invest"},{"key":"10.1016\/j.jid.2020.06.019_bib4","article-title":"Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn\u2019s disease [e-pub ahead of print]","author":"Berman","year":"2019","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2020.06.019_bib5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1146\/annurev.iy.07.040189.003205","article-title":"The biology of cachectin\/TNF--a primary mediator of the host response","volume":"7","author":"Beutler","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.jid.2020.06.019_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1111\/bjd.14338","article-title":"Ustekinumab in hidradenitis suppurativa: clinical results and a search for potential biomarkers in serum","volume":"174","author":"Blok","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2133.2010.10071.x","article-title":"Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer?","volume":"164","author":"Boer","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib8","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/jid.2012.472","article-title":"Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study","volume":"133","author":"Canoui-Poitrine","year":"2013","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib9","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.jaad.2018.11.035","article-title":"Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment clinical and ultrasound observations","volume":"80","author":"Caposiena Caro","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib10","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/j.jaad.2020.02.005","article-title":"Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial","volume":"82","author":"Casseres","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib11","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jdcr.2017.12.010","article-title":"Ertapenem rescue therapy in hidradenitis suppurativa","volume":"4","author":"Chahine","year":"2018","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2020.06.019_bib12","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","article-title":"Topical treatment of hidradenitis suppurativa with clindamycin","volume":"22","author":"Clemmensen","year":"1983","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib13","article-title":"Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley stage 1 hidradenitis suppurativa: prospective short-term trial and one-year follow-up in 28 consecutive patients [e-pub ahead of print]","author":"Delage","year":"2020","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00403-017-1769-5","article-title":"IL-36 cytokines are increased in acne and hidradenitis suppurativa","volume":"309","author":"Di Caprio","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jid.2020.06.019_bib15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jid.2020.06.019_bib16","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3389\/fimmu.2019.00302","article-title":"Commentary: hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model","volume":"10","author":"Frew","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2020.06.019_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319830646","article-title":"Topical, systemic and biologic therapies in Hidradenitis suppurativa: pathogenic insights by examining therapeutic mechanisms","volume":"10","author":"Frew","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.jid.2020.06.019_bib18","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.12688\/f1000research.17267.1","article-title":"A\u00a0systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa","volume":"7","author":"Frew","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.jid.2020.06.019_bib19","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","article-title":"Clinical response rates, placebo response rates, and significantly associated covariates are dependent upon choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data","volume":"82","author":"Frew","year":"2020","journal-title":"J\u00a0Acad Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib20","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1111\/bjd.18309","article-title":"Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies","volume":"181","author":"Frew","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib21","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jid.2020.02.014","article-title":"Ex\u00a0vivo models and interpretation of mechanistic studies in hidradenitis suppurativa","volume":"140","author":"Frew","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib22","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.jid.2019.09.009","article-title":"Role of the complement pathway in inflammatory skin diseases: a focus on hidradenitis suppurativa","volume":"140","author":"Ghias","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjd.18877","article-title":"Clinical efficacy of complement C5a inhibition by IFN-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab","volume":"183","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib24","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(18)32987-8","article-title":"JAK Inhibitors and alopecia areata","volume":"393","author":"Gilhar","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2020.06.019_bib26","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.jaad.2018.06.063","article-title":"Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa","volume":"80","author":"Golbari","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib27","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/jdv.14868","article-title":"Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders","volume":"32","author":"Gooderham","year":"2018","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"Suppl. 1","key":"10.1016\/j.jid.2020.06.019_bib28","first-page":"AB111","article-title":"Efficacy and safety results of guselkumab, an anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis: a phase 2a, randomized, double-blind, placebo-controlled study","volume":"76","author":"Gottlieb","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2019.10.024","article-title":"A\u00a0phase II open-label study of Bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain [e-pub ahead of print]","author":"Gottlieb","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib30","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/exd.14056","article-title":"Integrating complement into the molecular pathogenesis of hidradenitis suppurativa","volume":"29","author":"Grand","year":"2020","journal-title":"Exp Dermatol"},{"issue":"Suppl. 3","key":"10.1016\/j.jid.2020.06.019_bib31","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1177\/1203475417733414","article-title":"Acitretin use in dermatology","volume":"21","author":"Guenther","year":"2017","journal-title":"J\u00a0Cutan Med Surg"},{"key":"10.1016\/j.jid.2020.06.019_bib32","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3201\/eid2012.140064","article-title":"Bacterial pathogens associated with hidradenitis suppurativa, France","volume":"20","author":"Guet-Revillet","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.jid.2020.06.019_bib33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/cid\/cix285","article-title":"The microbiological landscape of anaerobic infections in hidradenitis suppurativa: a prospective metagenomic study","volume":"65","author":"Guet-Revillet","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jid.2020.06.019_bib34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1468-3083.2011.04123.x","article-title":"Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa","volume":"26","author":"Gulliver","year":"2012","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2020.06.019_bib35","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.16019","article-title":"Interleukin-36 in hidradenitis suppurativa: evidence for a distinctive proinflammatory role and a key factor in the development of an inflammatory loop","volume":"178","author":"Hessam","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203672","article-title":"Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature","volume":"13","author":"Hoffman","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jid.2020.06.019_bib37","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.jid.2016.04.036","article-title":"Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa","volume":"136","author":"Hotz","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib38","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bjd.16101","article-title":"Population-based Clinical Practice Research Datalink study using algorithm modelling to identify the true burden of hidradenitis suppurativa","volume":"178","author":"Ingram","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib39","first-page":"CD010081","article-title":"Interventions for hidradenitis suppurativa","volume":"2015","author":"Ingram","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jid.2020.06.019_bib40","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","article-title":"Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa","volume":"39","author":"Jemec","year":"1998","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cyto.2017.12.020","article-title":"Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa","volume":"103","author":"Jim\u00e9nez-Gallo","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.jid.2020.06.019_bib42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000321716","article-title":"Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa","volume":"222","author":"Join-Lambert","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2020.06.019_bib43","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jac\/dkv361","article-title":"Efficacy of ertapenem in severe hidradenitis suppurativa: a pilot study in a cohort of 30 consecutive patients","volume":"71","author":"Join-Lambert","year":"2016","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.jid.2020.06.019_bib44","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"Dinarello CAMABp1 targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib45","first-page":"413","article-title":"Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?","volume":"179","author":"Kanni","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib46","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.cell.2010.03.002","article-title":"Autoinflammatory disease reloaded: a clinical perspective","volume":"140","author":"Kastner","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jid.2020.06.019_bib47","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1111\/bjd.14075","article-title":"Dysregulated cytokine expression in lesional and nonlesional skin in Hidradenitis suppurativa","volume":"173","author":"Kelly","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib48","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/1740774515602688","article-title":"Fallacies of last observation carried forward analyses","volume":"13","author":"Lachin","year":"2016","journal-title":"Clin Trials"},{"key":"10.1016\/j.jid.2020.06.019_bib49","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.jid.2020.06.019_bib50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jaad.2013.10.043","article-title":"Specific targeting of interleukin-23p19 as effective treatment for psoriasis","volume":"70","author":"Levin","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib51","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/s41590-019-0514-y","article-title":"IL-17 receptor-based Signaling and implications for disease","volume":"20","author":"Li","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2020.06.019_bib52","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjd.14214","article-title":"Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa","volume":"174","author":"Lima","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib53","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ni.1610","article-title":"The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat","volume":"9","author":"Manel","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2020.06.019_bib54","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jdcr.2018.12.002","article-title":"Secukinumab and hidradenitis suppurativa: friends or foes?","volume":"5","author":"Marasca","year":"2019","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2020.06.019_bib55","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1111\/pde.13143","article-title":"Dissecting cellulitis of the scalp with excellent response to isotretinoin","volume":"34","author":"Marquis","year":"2017","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib56","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/jdv.16183","article-title":"Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study","volume":"34","author":"Martorell","year":"2020","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2020.06.019_bib57","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s12016-017-8621-8","article-title":"A\u00a0comprehensive review of neutrophilic diseases","volume":"54","author":"Marzano","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jid.2020.06.019_bib58","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1097\/MD.0000000000000187","article-title":"Association of pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) shares genetic and cytokine profiles with other autoinflammatory diseases","volume":"93","author":"Marzano","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jid.2020.06.019_bib59","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1111\/bjd.15226","article-title":"Autoinflammation in pyoderma gangrenosum and its syndromic form (pyoderma gangrenosum, acne and suppurative hidradenitis)","volume":"176","author":"Marzano","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib60","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2340\/00015555-0749","article-title":"Increased serum tumour necrosis factor-\u03b1 in hidradenitis suppurativa patients: is there a basis for treatment with anti-tumour necrosis factor-\u03b1 agents?","volume":"89","author":"Matusiak","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2020.06.019_bib61","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/bjd.12884","article-title":"Acitretin treatment for hidradenitis suppurativa: a prospective series of 17 patients","volume":"171","author":"Matusiak","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib62","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2016.10.042","article-title":"Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: implications for treatment with anti-IL-17 agents","volume":"76","author":"Matusiak","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib63","first-page":"260","article-title":"T\u00a0helper 17 cell\/regulatory T-cell imbalance in hidradenitis suppurativa\/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities","volume":"179","author":"Melnik","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib64","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1016\/j.jid.2017.05.033","article-title":"Hidradenitis suppurativa is characterized by dysregulation of the Th17:Treg cell axis, which is corrected by anti-TNF therapy","volume":"137","author":"Moran","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib65","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2340\/00015555-1492","article-title":"Tumor necrosis factor-alpha and matrix metalloproteinase-2 are expressed strongly in Hidradenitis suppurativa","volume":"93","author":"Mozeika","year":"2013","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jid.2020.06.019_bib66","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jid.2019.08.445","article-title":"Skin microbiota perturbations are distinct and disease severity-dependent in hidradenitis suppurativa","volume":"140","author":"Naik","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib67","doi-asserted-by":"crossref","first-page":"e13150","DOI":"10.1111\/dth.13150","article-title":"Secukinumab-induced paradoxical hidradenitis suppurativa","volume":"33","author":"Navarro-Trivi\u00f1o","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jid.2020.06.019_bib68","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/bjd.18556","article-title":"Interleukin 17C is elevated in lesional skin of hidradenitis suppurativa","volume":"182","author":"Navrazhina","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib69","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for Moderate-to-Severe Plaque Psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jid.2020.06.019_bib70","article-title":"Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study [e-pub ahead of print]","author":"Patel","year":"2019","journal-title":"J\u00a0Dermatolog Treat"},{"key":"10.1016\/j.jid.2020.06.019_bib71","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2020.06.019_bib72","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jid.2020.06.019_bib73","first-page":"239","article-title":"The role of androgens and estrogens in hidradenitis suppurativa - a systematic review","volume":"24","author":"Riis","year":"2016","journal-title":"Acta Dermatovenerol Croat"},{"key":"10.1016\/j.jid.2020.06.019_bib74","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/jdv.15597","article-title":"The microbiome of tunnels in hidradenitis suppurativa patients","volume":"33","author":"Ring","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2020.06.019_bib75","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamadermatol.2017.0904","article-title":"The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls","volume":"153","author":"Ring","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib77","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jid.2020.06.019_bib78","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/s41590-018-0155-6","article-title":"Translational repression of pre-formed cytokine-encoding mRNA prevents chronic activation of memory T cells","volume":"19","author":"Salerno","year":"2018","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2020.06.019_bib79","doi-asserted-by":"crossref","DOI":"10.1177\/2040622319851640","article-title":"TNF-\u03b1 inhibitors in the treatment of hidradenitis suppurativa","volume":"10","author":"Savage","year":"2019","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.jid.2020.06.019_bib80","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jdcr.2019.10.010","article-title":"Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients","volume":"6","author":"Savage","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jid.2020.06.019_bib81","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jaad.2010.07.010","article-title":"Expression of the IL-23\/Th17 pathway in lesions of hidradenitis suppurativa","volume":"65","author":"Schlapbach","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib82","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.jid.2019.06.151","article-title":"Loss of skin microbial diversity and alteration of bacterial metabolic function in Hidradenitis suppurativa","volume":"140","author":"Schneider","year":"2020","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib83","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2020.06.019_bib84","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/jdv.14389","article-title":"Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa","volume":"31","author":"Thomi","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2020.06.019_bib85","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/exd.13482","article-title":"Elevated levels of the antimicrobial peptide LL-37 in hidradenitis suppurativa are associated with a Th1\/Th17 immune response","volume":"27","author":"Thomi","year":"2018","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib86","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/bjd.15458","article-title":"Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa","volume":"177","author":"Thomi","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib87","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjd.17716","article-title":"Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa","volume":"181","author":"Thorlacius","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib88","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3389\/fimmu.2019.00892","article-title":"An integrated approach to unravel hidradenitis suppurativa etiopathogenesis","volume":"10","author":"Tricarico","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2020.06.019_bib89","doi-asserted-by":"crossref","first-page":"4097574","DOI":"10.1155\/2016\/4097574","article-title":"MMP8 is increased in lesions and blood of acne inversa patients: a potential link of skin destruction and metabolic alterations","volume":"2016","author":"Tsaousi","year":"2016","journal-title":"Mediators inflamm"},{"key":"10.1016\/j.jid.2020.06.019_bib90","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized clinical trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib91","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","article-title":"Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2","volume":"164","author":"van der Zee","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib92","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1468-3083.2012.04668.x","article-title":"Metformin for the treatment of hidradenitis suppurativa: a little help along the way","volume":"27","author":"Verdolini","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jid.2020.06.019_bib93","first-page":"155","article-title":"Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age","volume":"150","author":"Verdolini","year":"2015","journal-title":"G\u00a0Ital Dermatol Venereol"},{"key":"10.1016\/j.jid.2020.06.019_bib94","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/ni.1613","article-title":"A\u00a0critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses","volume":"9","author":"Volpe","year":"2008","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jid.2020.06.019_bib95","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000335373","article-title":"Morphology of pilonidal sinus disease: some evidence of its being a unilocalized type of hidradenitis suppurativa","volume":"223","author":"von Laffert","year":"2011","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2020.06.019_bib96","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaad.2016.07.024","article-title":"Menses and pregnancy affect symptoms in hidradenitis suppurativa: a cross-sectional study","volume":"76","author":"Vossen","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib97","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1038\/jid.2014.308","article-title":"IL-19 is a component of the pathogenetic IL-23\/IL-17 cascade in psoriasis","volume":"134","author":"Witte","year":"2014","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib98","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.jid.2018.11.018","article-title":"The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction","volume":"139","author":"Witte-H\u00e4ndel","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2020.06.019_bib99","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa","volume":"186","author":"Wolk","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.jid.2020.06.019_bib100","doi-asserted-by":"crossref","first-page":"204ra129","DOI":"10.1126\/scitranslmed.3006245","article-title":"IL-29 is produced by T(H)17 cells and mediates the cutaneous antiviral competence in psoriasis","volume":"5","author":"Wolk","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jid.2020.06.019_bib101","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/jid.2014.98","article-title":"IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing \u03b3\u03b4 T cells","volume":"134","author":"Yoshiki","year":"2014","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20318261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X20318261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T17:19:34Z","timestamp":1758302374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X20318261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0022202X20318261"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2020.06.019","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2020.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}